The therapy of Alzheimer's disease with BMRT is still in clinical testing stage. However, the results to date clearly indicate that it at least slows down the progression of the disease.

​

Results:

Total: 34 patients (4.2% - clinical testing stage)

Pre-treatment average: VAS 1.0 points

Post treatment average: VAS 6.9 points

1 year post treatment average: VAS 6.4 points of maximum 10 points

​​​

Conclusion:

General health condition – health improvement according to the patient's subjective perception

 

Total: 817 (100 % - all patients with various indications)

Pre-treatment average: VAS 1.4 points

Post treatment average: VAS 9.5 points

1 year post treatment average: VAS 9.2 points of maximum 10 points

​

In summary, it can be stated that longevity, health condition and patients’ personal perception of well-being improved significantly after BMRT® Ultra High Dosage Antibody Therapy in all indications described.